Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02871492 · ClinicalTrials.gov registry record · Phase 2
Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes
A Phase 2 study, sponsored by AiCuris Anti-infective Cures.
- Completed
- Registry status
- Phase 2
- Development phase
- 362
- Enrollment target
NCT02871492 is a Phase 2 study that has completed, run by AiCuris Anti-infective Cures. The registered enrollment target is 362 participants.
The verdict
NCT02871492, a Phase 2 study, has completed, sponsored by AiCuris Anti-infective Cures.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 362 participants
- Enrollment target
Study Summary
Randomized, double-blind, multi-center, three arm parallel group, comparative trial to assess pritelivir ointment safety and efficacy, ie, proportion of subjects with non-ulcerative lesions, in adult subjects with recurrent herpes labialis (RHL) in comparison with placebo or Zovirax® Cream. The start of treatment with trial medication will be initiated by the subject within one hour of noticing the first sign or symptom (eg, prodrome) of a recurrence of herpes labialis. Trial medication will be applied to the affected area 5 times daily for 4 days. After self-initiation of treatment with trial medication subjects will be assessed daily by the Investigator until complete healing for a maximum of 13 days. Subjects will document application of trial medication and the status of their lesion in a diary. There will also be blood sampling, ECG measurement and physical examination performed at the investigational site.
Interventions
- DRUG Pritelivir 5% w/w ointment
- DRUG Pritelivir ointment matching placebo
- DRUG Zovirax® cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 362 participants |
| Start Date | 2016-11-29 |
| Est. Completion | 2017-10-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02871492
The ClinicalTrials.gov registry entry for NCT02871492 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 362 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AiCuris Anti-infective Cures, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pritelivir 5% w/w ointment is the first listed.
NCT02871492 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02871492 about?
NCT02871492 is a clinical study titled "Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes". Randomized, double-blind, multi-center, three arm parallel group, comparative trial to assess pritelivir ointment safety and efficacy, ie, proportion of subjects with non-ulcerative lesions, in adult subjects with recurrent herpes labialis (RHL) in comparison with placebo or Zovirax® Cream. The star...
What is the current status of trial NCT02871492?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 362 participants. The study started on 2016-11-29. Estimated completion is 2017-10-16.
What interventions are being tested in trial NCT02871492?
The interventions under investigation include: Pritelivir 5% w/w ointment (DRUG), Pritelivir ointment matching placebo (DRUG), Zovirax® cream (DRUG).
Who is sponsoring clinical trial NCT02871492?
This trial is sponsored by AiCuris Anti-infective Cures, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.